Polyiodide binding compounds are described herein along with compounds and methods that are useful in brachytherapy. A compound of the present invention may comprise: a polyiodide binding matrix; a protecting group attached to the polyiodide binding matrix optionally via a linker, and optionally a cross-linking moiety attached to the polyiodide binding matrix. Compounds and methods of the present invention may be used for localizing a radioactive compound.

Described are amphiphilic polymers that are provided with chelating moieties. The amphiphilic polymers are block copolymers comprising a hydrophilic block and a hydrophobic block, with the chelating moieties linked to the end-group of the hydrophilic block. The disclosed polymers are capable of self-assembly into structures such as micelles and polymersomes. With suitable metals present in the form of coordination complexes with the chelating moieties, the chelating amphiphilic polymers of the invention are suitable for use in various imaging techniques requiring metal labeling, such as MRI (T.sub.1/T.sub.2 weighted contrast agents or CEST contrast agents) SPECT, PET or Spectral CT.

The invention relates to a kit for preparation of target radiopharmaceuticals, a method of using the kit to prepare target radiopharmaceuticals and use of the target radiopharmaceuticals. The target radiopharmaceuticals comprise a radio-nuclear loading on liposome and inhibit the tumor growth and metastatic progression of head and neck cancer, lung cancer and brain cancer. The radiopharmaceuticals may be used for treating the mentioned cancers.

The present invention provides multi-armed high MW polymers containing hydrophilic groups and one or more functional agents, and methods of preparing such polymers.

The invention provides a compound having the following structure:

D-DT-R,

wherein D is a dextran molecule or a charged dextran molecule having a molecular weight between about 50,000 and about 110,000 Daltons, DT is dodecane tetra-acetic acid (DOTA) or a conjugate base thereof, and R is a radioactive isotope. The invention also provides a method for treating body cavity cancer in a patient afflicted therewith, comprising administering an effective amount of a dextran—dodecane tetraacetic acid—radioactive isotope compound in a pharmaceutically effective vehicle.

Compositions and methods of using these compositions that can include a targeting moiety and a therapeutic agent are described herein. These compositions can be used for treating inflammatory diseases, such as parasitic diseases that result in cutaneous lesions. For example, and without limitation, such an parasitic disease can be leishmaniasis.

The present invention provides certain compounds, or salts or solvates thereof, which can be used as matrix metalloproteinase-targeted inhibitors or imaging agents.

##STR00001##

Provided herein are nanoplexes comprising a payload selected from a protein and/or a polynucleic acid; and a plurality of copolymers comprising a first copolymer that is poly(N,N′-bis(acryloyl)cystamine-poly(aminoalkyl)) (PBAP), a second copolymer that is poly(C.sub.2-3 akylene glycol)-PBAP-poly(C.sub.2-3 akylene glycol), and a third copolymer that is TG-poly(C.sub.2-3 akylene glycol)-PBAP-poly(C.sub.2-3 akylene glycol)-TG wherein TG at each occurrence is independently a targeting ligand, a cell penetrating peptide, an imaging agent or a capping group, provided that a plurality of TG groups is a targeting ligand; wherein the payload is non-covalently complexed to one or more of the copolymers, one or more of the first, second, and/or third copolymers comprises an endosomal escape group having a pKa of about 4.5 to about 6.5, and optionally one or more of the first, second, and/or third copolymers comprises a host and a guest non-covalent crosslinker.

The invention provides a compound having the following structure:
T-DOTA-R,
wherein T is a carbohydrate polymer, R is a radioactive isotope, DOTA is a chelator of R, and T is covalently bond to DOTA. In one embodiment, the carbohydrate polymer is hyaluronic acid (HA). The compound or HA is used alone as a polymer or incorporated into a hydrogel for treating body cavity cancer, comprising administering an effective amount of the compound or hydrogel. The invention also provides a method for treating body cavity or soft tissue cancer comprising: introducing into the affected area a thermo reversible gel comprising the compound or HA, allowing the radioactive isotope to emit a therapeutic radiation to affected regions; and, after a predetermined time, optionally removing the gel from the body cavity with a cold rinse to liquefy the gel and allow it to exit the body cavity.

Process for preparation of polymeric nanoparticles that chelate radioactive isotopes and have their surface modified with specific molecules targeting PSMA receptor on the surface of cancer cells, with a targeting agent modified by a linker molecule attaching to free aldehyde groups present in the dextran chain. Polymeric nanoparticles that chelate radioactive isotopes synthesized according to the claimed process for use in therapy and diagnostics of prostate cancer and metastatic cancer cells as well as other affected cells for which the nanoparticles show the affinity.